Recent developments in the treatment of aggressive non-Hodgkin lymphoma
AS Michallet, B Coiffier - Blood reviews, 2009 - Elsevier
Options for treating aggressive non-Hodgkin lymphoma (NHL) have expanded in recent
years. In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine,
doxorubicin, and prednisone (CHOP) every 3 weeks (R-CHOP-21) has been associated
with improved survival, without increased toxicity, in all patient groups studied. Giving dose-
dense CHOP–CHOP every 2 weeks (CHOP-14)–has also proved appropriate for all patients
18–75 years old. Studies combining these approaches–dose-dense CHOP with rituximab (R …
years. In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine,
doxorubicin, and prednisone (CHOP) every 3 weeks (R-CHOP-21) has been associated
with improved survival, without increased toxicity, in all patient groups studied. Giving dose-
dense CHOP–CHOP every 2 weeks (CHOP-14)–has also proved appropriate for all patients
18–75 years old. Studies combining these approaches–dose-dense CHOP with rituximab (R …
